Xenetic Biosciences, Inc.
XBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534525
No open-market purchases or sales by Xenetic Biosciences, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $442.8K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Xenetic Biosciences, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −10 vs. Q1 2023
- Shares held
- 36.6K
- −21.2K (−36.6%) vs. Q1 2023Converted for a 1-for-10 split
- Total value
- $120.4K
- −$114.9K (−48.8%) vs. Q1 2023
- New holders
- 1
- 2 more added
- Sold out
- 11
- 2 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $442.8K |
| Q1 2026 | 6 | $453.0K |
| Q4 2025 | 11 | $496.6K |
| Q3 2025 | 10 | $183.7K |
| Q2 2025 | 9 | $250.2K |
| Q1 2025 | 13 | $293.1K |
| Q4 2024 | 13 | $356.1K |
| Q3 2024 | 9 | $211.6K |
| Q2 2024 | 5 | $62.0K |
| Q1 2024 | 7 | $73.8K |
| Q4 2023 | 7 | $60.7K |
| Q3 2023 | 7 | $79.4K |
| Q2 2023 | 9 | $120.4K |
| Q1 2023 | 19 | $235.3K |
| Q4 2022 | 19 | $197.6K |
| Q3 2022 | 16 | $535.0K |
| Q2 2022 | 15 | $828.0K |
| Q1 2022 | 14 | $1.07M |
| Q4 2021 | 22 | $1.88M |
| Q3 2021 | 19 | $3.43M |
| Q2 2021 | 14 | $832.2K |
| Q1 2021 | 12 | $1.22M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Xenetic Biosciences, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 25,782 | $85.0K | 0.00% | +15,831+159.1% | AddedConverted for a 1-for-10 split |
| Royal Bank of Canada | 5,300 | $17.0K | 0.00% | +5,300 | New |
| JTC Employer Solutions Trusteee Ltd | 2,700 | $9.00K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Steward Partners Investment Advisory, LLC | 1,900 | $6.23K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Tower Research Capital LLC (TRC) | 621 | $2.04K | 0.00% | −514−45.3% | ReducedConverted for a 1-for-10 split |
| Morgan Stanley | 295 | $967 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| NewSquare Capital LLC | 26 | $85 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Wells Fargo & Company | 11 | $36 | 0.00% | +1+4.8% | AddedConverted for a 1-for-10 split |
| FMR LLC | 7 | $22 | 0.00% | −15−67.7% | ReducedConverted for a 1-for-10 split |
| Vanguard Group Inc | 0 | $0 | 0.00% | −9,698−100.0% | Sold outConverted for a 1-for-10 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −9,155−100.0% | Sold outConverted for a 1-for-10 split |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −7,782−100.0% | Sold outConverted for a 1-for-10 split |
| HRT Financial LP | 0 | $0 | 0.00% | −3,747−100.0% | Sold outConverted for a 1-for-10 split |
| State Street Corp | 0 | $0 | 0.00% | −3,467−100.0% | Sold outConverted for a 1-for-10 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −2,022−100.0% | Sold outConverted for a 1-for-10 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −1,776−100.0% | Sold outConverted for a 1-for-10 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,637−100.0% | Sold outConverted for a 1-for-10 split |
| Ergoteles LLC | 0 | $0 | 0.00% | −1,277−100.0% | Sold outConverted for a 1-for-10 split |
| Great Valley Advisor Group, Inc. | 0 | $0 | 0.00% | −1,060−100.0% | Sold outConverted for a 1-for-10 split |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −136−100.0% | Sold outConverted for a 1-for-10 split |